Program
bemnifosbuvir
Also written as “AT-527”, “Bemnifosbuvir (BEM)” and “AT-527 + digoxin”.
Its studies are mostly in Hepatitis C, Chronic · COVID-19 · Renal Insufficiency, led by 2 companies.
Drug pageBemnifosbuvir: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Atea Pharmaceuticalsits history only | 240 open or running | phase 3since Nov 26, 2022 | Jul 13, 2017 | none ahead |
| Hoffmann-La Roche | 20 open or running | phase 3since May 10, 2021 | Jan 12, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Hoffmann-La Roche only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jan 12, 2021First study: phase 2 study in COVID-19First studyNCT04709835 · 104 enrolled · Canada, Greece, Ireland and more
- May 10, 2021Phase 3 study in COVID-19NCT04889040 · 216 enrolled · Argentina, Belgium, Brazil and more
- Jul 28, 2021Named bemnifosbuvirINNProposed as its International Nonproprietary Name in WHO's List 125 · before, AT-527
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 Hoffmann-La Roche leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04889040COVID-19 · Argentina, Belgium, Brazil and more | 3 | Terminated | Dec 2, 2021 | 216 |
| NCT04709835COVID-19 · Canada, Greece, Ireland and more | 2 | Completed | Sep 17, 2021 | 104 |
How it is read
Names in the registry
- “AT-527”, 10 entries
- “Bemnifosbuvir (BEM)”, 4 entries
- “AT-527 + digoxin”, 2 entries
- “AT-527 550 mg + midazolam”, 2 entries
- “Buprenorphine/Naloxone + BEM/RZR”, 1 entry
Conditions, from the studies’ own filings
- Hepatitis C, Chronic, 4 studies
- COVID-19, 4 studies
- Renal Insufficiency, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.